The company continues to execute its proven growth strategy which consists of leveraging its scale in high-growth and emerging markets and delivering a unique value proposition to its customers. The references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects, and other expenditures to enhance the customer experience. The company's productivity improvements generally refer to improved cost efficiencies from its practical process improvement business system, including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, and a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities. The acquisition of the European viral vector manufacturing business expands the segment's capabilities for cell and gene vaccines and therapies, while the acquisition of Mesa Biotech enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The addition of PPD's clinical research services enhances the offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The company evaluates segment operating performance using operating income before certain charges/credits, indicating a focus on operational efficiency and performance linkage. The increase in organic revenues in 2022 was due to increased demand across all the segment's businesses, with particular strength in the electron microscopy and chromatography and mass spectrometry businesses, highlighting the importance of technology capabilities in driving business performance. The company’s references to investments in working capital reflect the need for resource deployment to support growth in sales, demonstrating a commitment to aligning technology resources with business needs. The company believes that its existing cash and cash equivalents, along with its future cash flow from operations, will be sufficient to meet the cash requirements of its existing businesses, indicating a strategic approach to resource management and operational flexibility. The company's ability to generate free cash flow and access capital markets underscores its operational effectiveness and strategic resource allocation. The company’s acquisitions and investments in technology infrastructure and capabilities are aimed at enhancing its competitive advantage and market responsiveness, which are critical in the evolving business environment. The company’s operational activities during 2022 included significant investments in property, plant, and equipment for capacity and capability investments, further emphasizing the focus on enhancing organizational capabilities and performance outcomes. The company’s strategic management practices and technology deployment are designed to support its business transformation initiatives, ensuring alignment with organizational goals and market dynamics.